Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India

Clinical trial NCT04541706 · COMPLETED

Trial details

NCT number: NCT04541706
Sponsor: Pfizer
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Advanced Non-Small Cell Lung Cancer

Start date: 2020-08-27
Primary completion: 2022-07-20
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.